<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495585</url>
  </required_header>
  <id_info>
    <org_study_id>120046</org_study_id>
    <secondary_id>12-DK-0046</secondary_id>
    <nct_id>NCT01495585</nct_id>
  </id_info>
  <brief_title>Lonafarnib for Chronic Hepatitis D</brief_title>
  <official_title>Treatment of Chronic Delta Hepatitis With Lonafarnib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

        -  Chronic hepatitis D is a severe disease of the liver caused by infection with the
           hepatitis D virus. The hepatitis D virus can only infect a person who also has hepatitis
           B; therefore, people with delta hepatitis have both hepatitis B and hepatitis D virus
           infection. Most people with hepatitis D eventually develop cirrhosis, which causes
           scarring and damage to the liver. There is currently no effective treatment for chronic
           hepatitis D.

        -  Lonafarnib is a drug that was originally designed to treat different types of cancer. It
           may be able to prevent the hepatitis D virus from reproducing itself. However, it has
           not been tested on people with hepatitis D. Researchers want to study different doses of
           lonafarnib to see how they affect virus levels and other symptoms of hepatitis D.

      Objectives:

      - To test the safety and effectiveness of lonafarnib as a treatment for chronic hepatitis D.

      Eligibility:

      - Individuals at least 18 years of age who have chronic hepatitis D.

      Design:

        -  Participants will be screened with a medical history and physical exam. They will have
           blood and urine tests, eye exams, and imaging studies of the liver and gall bladder. A
           liver biopsy may also be performed.

        -  Participants will receive either lonafarnib or placebo twice a day for 28 days. For the
           first 3 days, participants will stay in the hospital to have frequent blood tests.
           Participants will have four more clinic visits (on days 7, 14, 21, and 28) for blood and
           urine tests. Eye exams and heart function tests will also be given. Men may be asked to
           provide sperm samples for further testing.

        -  After the 28 days of treatment, participants will stop taking the drug or placebo. They
           will have regular followup visits for up to 6 months after stopping treatment....
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with
      the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major
      structural protein (HDV antigen) for replication. We propose to treat between 12 and 14
      patients with chronic delta hepatitis using the farnesyltransferase inhibitor (FTI)
      lonafarnib for a duration of twenty-eight days. Farnesyltransferase inhibitors have not been
      used in the therapy of delta hepatitis. Patients with HBsAg and HDV RNA in serum, elevated
      aminotransferases, or moderate-to-severe chronic hepatitis and HDV antigen on liver biopsy
      will be enrolled. Before receiving therapy, patients will be monitored for at least three
      months with regular testing for alanine aminotransferase (ALT) levels and will undergo
      Clinical Center admission for medical evaluation and percutaneous liver biopsy. Two dosing
      groups of lonafarnib will be assessed, with a placebo cohort in each group. At each clinic
      visit, patients will be questioned about side effects and symptoms, undergo focused physical
      examination, and have blood drawn for complete blood counts, HDV RNA, and routine liver tests
      (including ALT, AST, alkaline phosphatase, direct and total bilirubin, and albumin). At
      two-week intervals, for a period of 28 days, patients will also be tested for HBsAg,
      anti-HBs, HBV DNA, and prothrombin time. At the end of 28 days of treatment, patients will
      undergo repeat physical examination, assessment of symptoms (using a symptom scale
      questionnaire), complete blood counts, routine liver tests, and hepatitis B and D viral
      markers. The primary therapeutic endpoint will be an improvement in quantitative serum HDV
      RNA levels after 28 days of lonafarnib therapy. The primary safety endpoint will be the
      ability to tolerate the drug at the prescribed dose for the 4 week duration. Several
      secondary endpoints will be measured, including side effects, ALT levels, and symptoms.
      Therapy will be stopped for intolerance to lonafarnib (which will be carefully defined). This
      study is designed as a phase 2a study assessing the safety, tolerance and antiviral activity
      of two dose levels of lonafarnib, a farnesyltransferase inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy.</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT Levels</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Hepatitis D</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lonafarnib 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lonafarnib</intervention_name>
    <description>Commercially approved products used to test the research hypothesis</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Age 18 years or above, male or female.

               2. Serum alanine or aspartate aminotransferase activities above the upper limit of
                  normal (ALT &gt; 41 or AST &gt; 31 U/L) on an average of three determinations taken
                  during the previous 6 months. The mean of the three determinations will be
                  defined as baseline levels.

               3. Presence of anti-HDV in serum.

               4. Evidence of chronic hepatitis on liver biopsy done within the previous 12 months
                  with a necroinflammatory score in histology activity index of at least 5 (out of
                  a maximum of 18) and at least 1 for hepatic fibrosis (out of a maximum of 6).

               5. Presence of HDV antigen in liver tissue or HDV RNA in serum.

               6. Written informed consent.

        EXCLUSION CRITERIA:

          1. Decompensated liver disease, defined by bilirubin &gt; 4mg/dL, albumin &lt; 3.0 gm/dL,
             prothrombin time &gt; 2 sec prolonged, or history of bleeding esophageal varices, ascites
             or hepatic encephalopathy. Laboratory abnormalities that are not thought to be due to
             liver disease may not necessarily require exclusion. Patients with ALT levels greater
             than 1000 U/L (&gt; 25 times ULN) will not be enrolled but may be followed until three
             determinations are below this level.

          2. Pregnancy or inability to practice adequate contraception, in women of childbearing
             potential or in spouses of such women. Adequate contraception is defined as vasectomy
             in men, tubal ligation in women, or use of two barrier methods such as condoms and
             spermicide combination, birth control pills, an intrauterine device, Depo-Provera, or
             Norplant.

          3. Significant systemic or major illnesses other than liver disease, including, but not
             limited to, congestive heart failure, renal failure (eGFR &lt; 50 ml/min), organ
             transplantation, serious psychiatric disease or depression (only if felt to be at high
             risk by the NIH psychiatric consultation service), and active coronary artery disease.

          4. Systemic immunosuppressive therapy within the previous 2 months.

          5. Evidence of another form of liver disease in addition to viral hepatitis (for example
             autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis,
             Wilson disease, alcoholic liver disease, nonalcoholic steatohepatitis (but not
             steatosis), hemochromatosis, or alpha-1-antitrypsin deficiency).

          6. Active substance abuse, such as alcohol, inhaled or injection drugs within the
             previous year.

          7. Evidence of hepatocellular carcinoma.

          8. Evidence of concurrent hepatitis C infection with positive serum HCV RNA.

          9. Any experimental therapy apart from pegylated interferon within 6 months prior to
             enrollment.

         10. Diagnosis of malignancy in the five years prior to the enrollment with exception
             granted to superficial dermatologic malignancies.

         11. Evidence of HIV co-infection; HIV (Omega) antibody positivity on serum testing.

         12. Concurrent usage of statins as these drugs inhibit mevalonate synthesis which reduces
             protein prenylation.

         13. Concurrent usage of moderate and strong CYP3A inhibitors and inducers.

         14. Inability to understand or sign informed consent.

         15. Any other condition, which in the opinion of the investigators would impede the
             patient s participation or compliance in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theo Heller, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2012-DK-0046.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Glenn JS, Marsters JC Jr, Greenberg HB. Use of a prenylation inhibitor as a novel antiviral agent. J Virol. 1998 Nov;72(11):9303-6.</citation>
    <PMID>9765479</PMID>
  </reference>
  <reference>
    <citation>Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. 1990 Mar;8 Suppl:S10-4; discussion S21-3. Review.</citation>
    <PMID>2183511</PMID>
  </reference>
  <reference>
    <citation>Rosina F, Rizzetto M. Treatment of chronic type D (delta) hepatitis with alpha interferon. Semin Liver Dis. 1989 Nov;9(4):264-6. Review.</citation>
    <PMID>2690350</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2011</study_first_submitted>
  <study_first_submitted_qc>December 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2011</study_first_posted>
  <results_first_submitted>April 28, 2016</results_first_submitted>
  <results_first_submitted_qc>July 18, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2016</results_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Delta</keyword>
  <keyword>Treatment</keyword>
  <keyword>Lonafarnib</keyword>
  <keyword>Hepatitis D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis D</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified data with outside collaborators</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In Group 1, participants were randomized either placebo or lonafarnib 100 mg. In Group2, participants were randomized into either placebo or lonafarnib 200 mg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Two placebo participants in Group1 and two placebo participants in Group 2. The two placebo participants in Group 1 received open label lonafarnib 200 mg.</description>
        </group>
        <group group_id="P2">
          <title>Lonafarnib 100 mg</title>
          <description>6 participants were randomized to Lonafarnib 100 mg.</description>
        </group>
        <group group_id="P3">
          <title>Lonafarnib 200 mg</title>
          <description>4 participants were randomized to Lonafarnib 200 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Open Label Lonafarnib 200 mg</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled patients were sequentially assigned into one of two dosing groups which consisted of lonafarnib 100mg in group 1 and lonafarnib 200mg in group 2, with placebo controls in each group.
Group1 placebo patients received open-label lonafarnib as group 2 participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo control.</description>
        </group>
        <group group_id="B2">
          <title>Lonafarnib 100 mg</title>
          <description>6 participants were randomized to Lonafarnib 100 mg.</description>
        </group>
        <group group_id="B3">
          <title>Lonafarnib 200 mg</title>
          <description>4 participants were randomized to Lonafarnib 200 mg and two &quot;Placebo&quot; participants in Lonafarnib 100 mg arm received open label lonafarnib 200 mg .</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" lower_limit="33" upper_limit="39"/>
                    <measurement group_id="B2" value="36" lower_limit="30" upper_limit="42"/>
                    <measurement group_id="B3" value="45" lower_limit="38" upper_limit="55"/>
                    <measurement group_id="B4" value="38" lower_limit="33" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" lower_limit="24.1" upper_limit="28.9"/>
                    <measurement group_id="B2" value="22.8" lower_limit="21.9" upper_limit="23.5"/>
                    <measurement group_id="B3" value="26.1" lower_limit="25.5" upper_limit="27.3"/>
                    <measurement group_id="B4" value="24.4" lower_limit="21.9" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-treatment mucleoside analogues</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnic origin</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy.</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo control.
Group 1 placebo participants received open-label lonafarnib as group 2 participants.
Each group consisted of 8 participants (6 lonafarnib ands 2 placebo).</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>lonafarnib 100 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>lonafarnib 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy.</title>
          <units>log(IU/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.14"/>
                    <measurement group_id="O2" value="-0.73" spread="0.54"/>
                    <measurement group_id="O3" value="-1.54" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Student t-test was used on the change in serum log HDV RNA after 28 days of therapy with lonafarnib.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Student t-test was used on the change in serum log HDV RNA after 28 days of therapy with lonafarnib.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Levels</title>
        <time_frame>7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo control.
Group 1 placebo participants received open-label lonafarnib as group 2 participants.
Each group consisted of 8 participants (6 lonafarnib ands 2 placebo).</description>
          </group>
          <group group_id="O2">
            <title>Group 1</title>
            <description>lonafarnib 100 mg</description>
          </group>
          <group group_id="O3">
            <title>Group 2</title>
            <description>lonafarnib 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>ALT Levels</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="13"/>
                    <measurement group_id="O2" value="4" spread="93"/>
                    <measurement group_id="O3" value="29" spread="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo control.
Group 1 placebo participants received open-label lonafarnib as group 2 participants.
Each group consisted of 8 participants (6 lonafarnib ands 2 placebo).</description>
        </group>
        <group group_id="E2">
          <title>Group 1</title>
          <description>lonafarnib 100 mg</description>
        </group>
        <group group_id="E3">
          <title>Group 2</title>
          <description>lonafarnib 200 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Abdominal bloating/dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight loss &gt; 2kg</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Theo Heller</name_or_title>
      <organization>National Insitute of DIabetes and Digestive and Kidney Diseases</organization>
      <phone>301-402-7147</phone>
      <email>hellert@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

